Gensight Biologics (France) Probability of Future Stock Price Finishing Over 0.31

SIGHT Stock  EUR 0.31  0.01  3.13%   
Gensight Biologics' future price is the expected price of Gensight Biologics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Gensight Biologics SA performance during a given time horizon utilizing its historical volatility. Check out Gensight Biologics Backtesting, Gensight Biologics Valuation, Gensight Biologics Correlation, Gensight Biologics Hype Analysis, Gensight Biologics Volatility, Gensight Biologics History as well as Gensight Biologics Performance.
  
Please specify Gensight Biologics' target price for which you would like Gensight Biologics odds to be computed.

Gensight Biologics Target Price Odds to finish over 0.31

The tendency of Gensight Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.31 90 days 0.31 
about 91.0
Based on a normal probability distribution, the odds of Gensight Biologics to move above the current price in 90 days from now is about 91.0 (This Gensight Biologics SA probability density function shows the probability of Gensight Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days trading horizon Gensight Biologics has a beta of 0.91. This usually implies Gensight Biologics SA market returns are sensible to returns on the market. As the market goes up or down, Gensight Biologics is expected to follow. Additionally Gensight Biologics SA has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Gensight Biologics Price Density   
       Price  

Predictive Modules for Gensight Biologics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Gensight Biologics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Gensight Biologics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.020.314.57
Details
Intrinsic
Valuation
LowRealHigh
0.010.284.54
Details

Gensight Biologics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Gensight Biologics is not an exception. The market had few large corrections towards the Gensight Biologics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Gensight Biologics SA, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Gensight Biologics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.44
β
Beta against Dow Jones0.91
σ
Overall volatility
0.04
Ir
Information ratio -0.1

Gensight Biologics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Gensight Biologics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Gensight Biologics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Gensight Biologics generated a negative expected return over the last 90 days
Gensight Biologics has some characteristics of a very speculative penny stock
Gensight Biologics has high historical volatility and very poor performance
The company reported the revenue of 5.28 M. Net Loss for the year was (28.62 M) with profit before overhead, payroll, taxes, and interest of 7.71 M.
Gensight Biologics SA has accumulated about 44.29 M in cash with (17.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.06, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 13.0% of the company outstanding shares are owned by corporate insiders

Gensight Biologics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Gensight Stock often depends not only on the future outlook of the current and potential Gensight Biologics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Gensight Biologics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding45.2 M
Cash And Short Term Investments44.3 M

Gensight Biologics Technical Analysis

Gensight Biologics' future price can be derived by breaking down and analyzing its technical indicators over time. Gensight Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Gensight Biologics SA. In general, you should focus on analyzing Gensight Stock price patterns and their correlations with different microeconomic environments and drivers.

Gensight Biologics Predictive Forecast Models

Gensight Biologics' time-series forecasting models is one of many Gensight Biologics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Gensight Biologics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Gensight Biologics

Checking the ongoing alerts about Gensight Biologics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Gensight Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Gensight Biologics generated a negative expected return over the last 90 days
Gensight Biologics has some characteristics of a very speculative penny stock
Gensight Biologics has high historical volatility and very poor performance
The company reported the revenue of 5.28 M. Net Loss for the year was (28.62 M) with profit before overhead, payroll, taxes, and interest of 7.71 M.
Gensight Biologics SA has accumulated about 44.29 M in cash with (17.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.06, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 13.0% of the company outstanding shares are owned by corporate insiders

Additional Tools for Gensight Stock Analysis

When running Gensight Biologics' price analysis, check to measure Gensight Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gensight Biologics is operating at the current time. Most of Gensight Biologics' value examination focuses on studying past and present price action to predict the probability of Gensight Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gensight Biologics' price. Additionally, you may evaluate how the addition of Gensight Biologics to your portfolios can decrease your overall portfolio volatility.